Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 756-763, November 2011

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma☆

  • Aymen A. Elfiky, M.D., M.A., M.P.H.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Daniel C. Cho, M.D., M.S.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • David F. McDermott, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Jonathan E. Rosenberg, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Barry Fortner, Ph.D.

      Affiliations

    • P4 Healthcare, Lakeland, TN 38002, USA
    • ,
  • Lucia Antràs, Ph.D.

      Affiliations

    • Analysis Group, Inc., Boston, MA 02115, USA
    • ,
  • Kristina Chen, Ph.D.

      Affiliations

    • Analysis Group, Inc., Boston, MA 02115, USA
    • ,
  • Mei Sheng Duh, Ph.D.

      Affiliations

    • Analysis Group, Inc., Boston, MA 02115, USA
    • ,
  • Sujata S. Jayawant, Ph.D.

      Affiliations

    • Analysis Group, Inc., Boston, MA 02115, USA
    • ,
  • William K. Oh, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Michael B. Atkins, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • ,
  • Toni K. Choueiri, M.D.

      Affiliations

    • Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-617-632-5456; fax: +1-617-632-2165

Received 18 December 2009; received in revised form 26 January 2010; accepted 26 January 2010. published online 10 May 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This research was supported in part by the DF/HCC Kidney Cancer SPORE.

PII: S1078-1439(10)00036-0

doi:10.1016/j.urolonc.2010.01.008

Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 756-763, November 2011

Article Tools

* Image Usage & Resolution